MX2021011160A - Derivado de heteroarilo, metodo para producirlo y composicion farmaceutica que lo comprende como componente eficaz. - Google Patents
Derivado de heteroarilo, metodo para producirlo y composicion farmaceutica que lo comprende como componente eficaz.Info
- Publication number
- MX2021011160A MX2021011160A MX2021011160A MX2021011160A MX2021011160A MX 2021011160 A MX2021011160 A MX 2021011160A MX 2021011160 A MX2021011160 A MX 2021011160A MX 2021011160 A MX2021011160 A MX 2021011160A MX 2021011160 A MX2021011160 A MX 2021011160A
- Authority
- MX
- Mexico
- Prior art keywords
- same
- pharmaceutical composition
- effective component
- heteroaryl derivative
- treatment
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 102000001301 EGF receptor Human genes 0.000 abstract 2
- 108060006698 EGF receptor Proteins 0.000 abstract 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 201000005202 lung cancer Diseases 0.000 abstract 2
- 208000020816 lung neoplasm Diseases 0.000 abstract 2
- HYJWBSPLCLPNOQ-UHFFFAOYSA-N 6-(1,2-oxazolidin-2-yl)-N-phenylpyrimidin-4-amine Chemical class O1N(CCC1)C1=CC(=NC=N1)NC1=CC=CC=C1 HYJWBSPLCLPNOQ-UHFFFAOYSA-N 0.000 abstract 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 abstract 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 abstract 1
- 102100029981 Receptor tyrosine-protein kinase erbB-4 Human genes 0.000 abstract 1
- 101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente invención se relaciona con un derivado de 6- (isooxazolidin-2-il)-N-fenilpirimidin-4-amina y una composición farmacéutica para prevenir o tratar el cáncer que comprende el compuesto como un componente eficaz. El compuesto exhibe elevada actividad inhibidora contra una variante del receptor de factor de crecimiento epidérmico (EGFR), o uno o más de ERBB2 y ERBB4 naturales o variantes de estos y, por lo tanto, puede usarse de manera útil en el tratamiento de cánceres en los que estos se expresan. En particular, el compuesto exhibe excelente actividad inhibidora sobre la proliferación de líneas celulares de cáncer de pulmón y, por lo tanto, puede usarse de manera útil en el tratamiento del cáncer de pulmón.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20190031269 | 2019-03-19 | ||
KR20190134472 | 2019-10-28 | ||
PCT/KR2020/095044 WO2020190119A1 (ko) | 2019-03-19 | 2020-03-19 | 헤테로아릴 유도체, 이를 제조하는 방법, 및 이를 유효성분으로 포함하는 약학적 조성물 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021011160A true MX2021011160A (es) | 2022-02-10 |
Family
ID=72521153
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021011160A MX2021011160A (es) | 2019-03-19 | 2020-03-19 | Derivado de heteroarilo, metodo para producirlo y composicion farmaceutica que lo comprende como componente eficaz. |
Country Status (15)
Country | Link |
---|---|
US (2) | US20220162203A1 (es) |
EP (1) | EP3943491A4 (es) |
JP (2) | JP7109013B2 (es) |
KR (2) | KR102318875B1 (es) |
CN (3) | CN115838369A (es) |
AU (1) | AU2020240382B2 (es) |
BR (1) | BR112021018704B1 (es) |
CA (1) | CA3134261A1 (es) |
IL (2) | IL299831A (es) |
MA (1) | MA55380A (es) |
MX (1) | MX2021011160A (es) |
NZ (1) | NZ781366A (es) |
SG (1) | SG11202110376XA (es) |
WO (1) | WO2020190119A1 (es) |
ZA (1) | ZA202107889B (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020190119A1 (ko) | 2019-03-19 | 2020-09-24 | 주식회사 보로노이 | 헤테로아릴 유도체, 이를 제조하는 방법, 및 이를 유효성분으로 포함하는 약학적 조성물 |
US20220289733A1 (en) * | 2019-03-19 | 2022-09-15 | Voronoi Inc. | Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component |
TW202227425A (zh) * | 2020-09-18 | 2022-07-16 | 南韓商沃若諾伊生物公司 | 雜芳基衍生物、彼之製法、及包含彼作為活性成份之藥學組成物 |
WO2022131741A1 (ko) * | 2020-12-14 | 2022-06-23 | 보로노이바이오 주식회사 | 아이소옥사졸리딘 유도체 화합물 및 이의 용도 |
JP2024516721A (ja) * | 2021-05-07 | 2024-04-16 | ボロノイ インコーポレイテッド | ヘテロアリール誘導体、これを製造する方法、およびこれを有効成分として含む薬学的組成物 |
KR102607051B1 (ko) * | 2021-05-17 | 2023-11-30 | 보로노이 주식회사 | 헤테로아릴 유도체 화합물 및 이의 용도 |
KR102563834B1 (ko) * | 2021-06-28 | 2023-08-04 | 순천대학교 산학협력단 | 세포자멸사를 유도하는 신규한 화합물 및 이를 포함하는 항암용 조성물 |
WO2024096624A1 (en) * | 2022-11-03 | 2024-05-10 | Voronoi Inc. | Fumarate, tartrate, malate, and citrate salts of an egfr inhibitor |
WO2024097848A1 (en) | 2022-11-03 | 2024-05-10 | Oric Pharmaceuticals, Inc. | Malonate and glycolate salts of an egfr inhibitor |
KR20240075718A (ko) * | 2022-11-15 | 2024-05-29 | 보로노이 주식회사 | 헤테로아릴 유도체 화합물 및 이의 용도 |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2318649T3 (es) | 2000-10-20 | 2009-05-01 | EISAI R&D MANAGEMENT CO., LTD. | Procedimiento de preparacion de derivados de 4-fenoxi quinolinas. |
US8084457B2 (en) | 2003-09-15 | 2011-12-27 | Lead Discovery Center Gmbh | Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases |
JP2008542219A (ja) | 2005-05-25 | 2008-11-27 | インゲニウム ファーマシューティカルズ ジーエムビーエイチ | 疼痛処置法 |
TW200804364A (en) | 2006-02-22 | 2008-01-16 | Boehringer Ingelheim Int | New compounds |
KR20090121399A (ko) | 2007-03-20 | 2009-11-25 | 스미스클라인 비참 코포레이션 | 화합물 |
TWI377944B (en) | 2007-06-05 | 2012-12-01 | Hanmi Holdings Co Ltd | Novel amide derivative for inhibiting the growth of cancer cells |
JP2011102241A (ja) | 2008-03-04 | 2011-05-26 | Dainippon Sumitomo Pharma Co Ltd | 新規1−アミノカルボニルピペリジン誘導体 |
CA2771190C (en) | 2009-08-17 | 2020-01-21 | Memorial Sloan-Kettering Cancer Center | Heat shock protein binding compounds, compositions, and methods for making and using same |
KR101401664B1 (ko) | 2011-11-15 | 2014-06-11 | 중앙대학교 산학협력단 | 신경줄기세포 분화조절제용 신규 피리미딘-2,4-디아민 유도체 및 이의 의학적 용도 |
JP6062962B2 (ja) | 2012-01-20 | 2017-01-18 | ジェノスコ | 置換ピリミジン化合物およびsyk阻害剤としてのそれらの使用 |
AU2013204563B2 (en) | 2012-05-05 | 2016-05-19 | Takeda Pharmaceutical Company Limited | Compounds for inhibiting cell proliferation in EGFR-driven cancers |
KR102194611B1 (ko) | 2012-10-04 | 2020-12-23 | 유니버시티 오브 유타 리서치 파운데이션 | 티로신 수용체 키나아제 btk 억제제로서 치환된 n-(3-(피리미딘-4-일)페닐)아크릴아미드 유사체 |
EP2769722A1 (en) | 2013-02-22 | 2014-08-27 | Ruprecht-Karls-Universität Heidelberg | Compounds for use in inhibiting HIV capsid assembly |
KR20150131224A (ko) | 2013-03-14 | 2015-11-24 | 노파르티스 아게 | 돌연변이 idh의 억제제로서의 3-피리미딘-4-일-옥사졸리딘-2-온 |
SG11201600759XA (en) | 2013-08-22 | 2016-03-30 | Taiho Pharmaceutical Co Ltd | Novel quinoline-substituted compound |
JP6487430B2 (ja) | 2013-10-21 | 2019-03-20 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | Btk阻害剤としてのヘテロアリール化合物及びその使用 |
KR20150047855A (ko) | 2013-10-25 | 2015-05-06 | 한미약품 주식회사 | 단백질 카이네이즈 억제 효과를 갖는 2-사이아노-아크릴아마이드 유도체 |
WO2015175632A1 (en) | 2014-05-13 | 2015-11-19 | Ariad Pharmaceuticals, Inc. | Heteroaryl compounds for kinase inhibition |
AU2015277786B2 (en) | 2014-06-19 | 2019-04-18 | Takeda Pharmaceutical Company Limited | Heteroaryl compounds for kinase inhibition |
CA2959194A1 (en) | 2014-10-11 | 2016-04-14 | Shanghai Hansoh Biomedical Co., Ltd. | 4-substituted-2-(n-(5-substituted allyl amide)phenyl)amino)pyrimidine compound, its use as an egfr inhibitor, and preparation and application thereof |
RU2020123547A (ru) * | 2014-10-13 | 2020-08-18 | Юхан Корпорейшн | Соединения и композиции для модуляции киназной активности мутантов egfr |
JP6649540B2 (ja) * | 2014-10-14 | 2020-02-19 | ノース・アンド・サウス・ブラザー・ファーマシー・インベストメント・カンパニー・リミテッド | 置換されたヘテロアリール化合物および使用方法 |
TWI739753B (zh) * | 2015-07-16 | 2021-09-21 | 大陸商正大天晴藥業集團股份有限公司 | 苯胺嘧啶衍生物及其用途 |
CN106478607B (zh) * | 2015-08-28 | 2019-05-24 | 广东东阳光药业有限公司 | 取代的杂芳基化合物及其组合物和用途 |
CN106132957B (zh) * | 2015-08-31 | 2018-06-12 | 无锡双良生物科技有限公司 | 2-芳胺基吡啶、嘧啶或三嗪衍生物及其制备方法和用途 |
US10709692B2 (en) | 2015-12-04 | 2020-07-14 | Denali Therapeutics Inc. | Isoxazolidine derived inhibitors of receptor interacting protein kinase 1 (RIPK1) |
US10435388B2 (en) * | 2016-01-07 | 2019-10-08 | Cs Pharmatech Limited | Selective inhibitors of clinically important mutants of the EGFR tyrosine kinase |
WO2017156527A1 (en) | 2016-03-11 | 2017-09-14 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Aurora kinase and janus kinase inhibitors for prevention of graft versus host disease |
US11072607B2 (en) | 2016-12-16 | 2021-07-27 | Genentech, Inc. | Inhibitors of RIP1 kinase and methods of use thereof |
JP7028900B2 (ja) * | 2017-06-13 | 2022-03-02 | ベイジン アダマドル バイオテクノロジー リミテッド ライアビリティ カンパニー | アミノピリミジン化合物、その調製方法、およびその使用 |
KR20200028966A (ko) * | 2017-07-05 | 2020-03-17 | 씨에스 파마테크 리미티드 | Efgr 티로신 키나제의 임상적으로 중요한 돌연변이체의 선택적 억제제 |
CA3079786A1 (en) | 2017-10-24 | 2019-05-02 | The Broad Institute, Inc. | 4h-pyrrolo[3,2-c]pyridin-4-one derivatives |
TWI798334B (zh) | 2018-01-31 | 2023-04-11 | 大陸商迪哲(江蘇)醫藥股份有限公司 | Erbb/btk抑制劑 |
CN108191774B (zh) | 2018-01-31 | 2022-05-24 | 中国药科大学 | 一类杂环化合物、其制备方法和用途 |
KR20190108079A (ko) | 2018-03-13 | 2019-09-23 | 보로노이바이오 주식회사 | 2,4,5-치환된 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물 |
KR20190108080A (ko) | 2018-03-13 | 2019-09-23 | 보로노이바이오 주식회사 | 2,4,5-치환된 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암 또는 염증질환의 예방 또는 치료용 약학적 조성물 |
AU2019269372A1 (en) | 2018-05-14 | 2020-11-26 | Takeda Pharmaceutical Company Limited | Pharmaceutical salts of pyrimidine derivatives and method of treating disorders |
CN109280048A (zh) | 2018-11-16 | 2019-01-29 | 江西科技师范大学 | 一种含取代苯基丙烯酰胺结构的嘧啶类化合物及其应用 |
CN109608394A (zh) | 2018-12-03 | 2019-04-12 | 湖南大学 | 氮杂芳胺类化合物的合成方法和氮杂芳胺类化合物 |
WO2020190119A1 (ko) | 2019-03-19 | 2020-09-24 | 주식회사 보로노이 | 헤테로아릴 유도체, 이를 제조하는 방법, 및 이를 유효성분으로 포함하는 약학적 조성물 |
-
2020
- 2020-03-19 WO PCT/KR2020/095044 patent/WO2020190119A1/ko active Application Filing
- 2020-03-19 NZ NZ781366A patent/NZ781366A/en unknown
- 2020-03-19 CN CN202211226875.4A patent/CN115838369A/zh active Pending
- 2020-03-19 IL IL299831A patent/IL299831A/en unknown
- 2020-03-19 CN CN202210215237.6A patent/CN114605400A/zh active Pending
- 2020-03-19 CA CA3134261A patent/CA3134261A1/en active Pending
- 2020-03-19 CN CN202080022186.4A patent/CN113993866B/zh active Active
- 2020-03-19 US US17/440,630 patent/US20220162203A1/en active Pending
- 2020-03-19 MA MA055380A patent/MA55380A/fr unknown
- 2020-03-19 JP JP2022504023A patent/JP7109013B2/ja active Active
- 2020-03-19 KR KR1020200033737A patent/KR102318875B1/ko active IP Right Grant
- 2020-03-19 MX MX2021011160A patent/MX2021011160A/es unknown
- 2020-03-19 SG SG11202110376XA patent/SG11202110376XA/en unknown
- 2020-03-19 AU AU2020240382A patent/AU2020240382B2/en active Active
- 2020-03-19 EP EP20774059.8A patent/EP3943491A4/en active Pending
- 2020-03-19 BR BR112021018704-9A patent/BR112021018704B1/pt active IP Right Grant
-
2021
- 2021-09-19 IL IL286471A patent/IL286471B2/en unknown
- 2021-10-15 ZA ZA2021/07889A patent/ZA202107889B/en unknown
- 2021-10-21 KR KR1020210141386A patent/KR102564533B1/ko active IP Right Grant
- 2021-11-08 US US17/521,711 patent/US11466000B2/en active Active
-
2022
- 2022-07-07 JP JP2022109721A patent/JP7394298B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
IL286471B1 (en) | 2023-04-01 |
JP7109013B2 (ja) | 2022-07-29 |
IL286471B2 (en) | 2023-08-01 |
BR112021018704B1 (pt) | 2023-01-10 |
US11466000B2 (en) | 2022-10-11 |
JP7394298B2 (ja) | 2023-12-08 |
JP2022125283A (ja) | 2022-08-26 |
EP3943491A4 (en) | 2022-11-23 |
CN113993866B (zh) | 2022-10-28 |
AU2022211789A1 (en) | 2022-08-25 |
CA3134261A1 (en) | 2020-09-24 |
BR112021018704A2 (es) | 2021-11-23 |
US20220162203A1 (en) | 2022-05-26 |
IL286471A (en) | 2021-12-01 |
JP2022522250A (ja) | 2022-04-14 |
EP3943491A1 (en) | 2022-01-26 |
SG11202110376XA (en) | 2021-10-28 |
KR102564533B1 (ko) | 2023-08-08 |
CN113993866A (zh) | 2022-01-28 |
KR20210130123A (ko) | 2021-10-29 |
AU2020240382A1 (en) | 2021-11-11 |
ZA202107889B (en) | 2024-02-28 |
AU2020240382B2 (en) | 2022-08-25 |
WO2020190119A1 (ko) | 2020-09-24 |
MA55380A (fr) | 2022-01-26 |
US20220073505A1 (en) | 2022-03-10 |
KR102318875B1 (ko) | 2021-11-01 |
NZ781366A (en) | 2022-08-26 |
CN115838369A (zh) | 2023-03-24 |
IL299831A (en) | 2023-03-01 |
CN114605400A (zh) | 2022-06-10 |
KR20200111644A (ko) | 2020-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA202107889B (en) | Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component | |
MX2022007515A (es) | Inhibidores de sos1. | |
CR20220169A (es) | Heterociclos bicíclicos como inhibidores de fgfr | |
WO2019177375A8 (ko) | 2, 4, 5-치환된 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물 | |
PH12019501116A1 (en) | Compounds with anti-tumor activity against cancer cells bearing egfr or her2 exon 20 | |
MY194058A (en) | Cyclic dinucleotides for treating conditions associated with sting activity such as cancer | |
WO2016161410A3 (en) | Treatment of cancer using inhibitors of tgf-beta and pd-1 | |
CR20220066A (es) | Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2 | |
WO2012016133A3 (en) | Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers | |
MY196811A (en) | Pharmaceutical composition for preventing or treating brain cancer including crystal polymorph of tetraarsenic hexoxide, and method for preparing same | |
MX2013004086A (es) | Metodos para inhibir proliferacion celular en cancers accionados por egfr. | |
PH12021550382A1 (en) | Tetrahydropyridopyrimidine derivatives as ahr modulators | |
MX2010005768A (es) | Composiciones y métodos para inhibir la activación del arnbc-dependiente de la proteina de la kinasa y la inhibición del crecimiento tumoral. | |
WO2019023315A3 (en) | RAC INHIBITORS | |
MX2022005749A (es) | Inhibidores de egfr alostericos y metodos de uso de los mismos. | |
AU2018380132A8 (en) | Tubulin inhibitors | |
WO2019177374A8 (ko) | 2, 4, 5-치환된 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암 또는 염증질환의 예방 또는 치료용 약학적 조성물 | |
MX2022000310A (es) | Inhibidores de proteina bcl-2. | |
MX2021011524A (es) | Inhibidores de proteina arginina n-metiltransferasa 5 (prmt5) y usos de los mismos. | |
MX2021009426A (es) | Derivados de indazolil-isoxazol para el tratamiento de enfermedades tales como cancer. | |
EP4011376A3 (en) | Combination of an alk inhibitor and an egfr inhibitor for treating cancer | |
WO2018218197A3 (en) | ATR KINASE INHIBITORS BASED ON TETRAHYDROPYRIDO [4,3-D] PYRIMIDINE | |
WO2018183370A3 (en) | Kdm4 inhibitors | |
WO2023086220A3 (en) | Papd5 inhibitors and methods of use thereof | |
MX2022015739A (es) | Inhibidores alostericos de egfr y metodos de uso de estos. |